Literature DB >> 14537113

Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts.

Elaine M Jagoda1, Luigi Aloj, Jurgen Seidel, Lixin Lang, Terry W Moody, Shielah Green, Corradina Caraco, Margaret Daube-Witherspoon, Michael V Green, William C Eckelman.   

Abstract

PURPOSE: A 18fluorine-labeled derivative of vasoactive intestinal peptide [18F- Arg,Arg VIP(18F-dVIP)] was evaluated as a potential imaging agent for breast cancer by comparison with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) using standard ex vivo determinations and small animal position emission tomography (PET) imaging. PROCEDURES: Human breast carcinomas, T-47D and MDA-MB231, tumor-bearing nude mice were injected intravenously with 18F-dVIP or FDG for imaging and/or biodistribution (ex vivo) determined by gamma counting.
RESULTS: FDG had two- to three-fold greater tumor accumulation and target-to-non target contrast relative to 18F-dVIP. VIP receptors were detected in both tumor types but in low concentrations (<15,000 receptors/cell) consistent with lower uptakes. FDG was cleared rapidly from non-target tissues while 18F-dVIP cleared into the kidneys.
CONCLUSIONS: 18F-dVIP uptake in mice T-47D tumors and kidneys determined by imaging correlated with values determined by ex vivo counting suggesting that tumor and other tissue uptakes can be quantified by in vivo positron projection imaging.

Entities:  

Year:  2002        PMID: 14537113     DOI: 10.1016/s1536-1632(02)00019-7

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  7 in total

1.  Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.

Authors:  Elaine M Jagoda; Sibaprasad Bhattacharyya; Joseph Kalen; Lisa Riffle; Avrum Leeder; Stephanie Histed; Mark Williams; Karen J Wong; Biying Xu; Lawrence P Szajek; Osama Elbuluk; Fabiola Cecchi; Kristen Raffensperger; Meghana Golla; Donald P Bottaro; Peter Choyke
Journal:  Mol Imaging       Date:  2015       Impact factor: 4.488

2.  Comparison of planar, PET and well-counter measurements of total tumor radioactivity in a mouse xenograft model.

Authors:  Michael V Green; Jurgen Seidel; Mark R Williams; Karen J Wong; Anita Ton; Falguni Basuli; Peter L Choyke; Elaine M Jagoda
Journal:  Nucl Med Biol       Date:  2017-06-30       Impact factor: 2.408

3.  In vivo positron emission tomography (PET) imaging with an alphavbeta6 specific peptide radiolabeled using 18F-"click" chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl- and 2-[18F]fluoropropionyl-peptides.

Authors:  Sven H Hausner; Jan Marik; M Karen J Gagnon; Julie L Sutcliffe
Journal:  J Med Chem       Date:  2008-09-12       Impact factor: 7.446

4.  Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Chirag A Patel; Satish Rattan; Gregory Cesarone; Eric Wickstrom; Mathew L Thakur
Journal:  Regul Pept       Date:  2007-07-06

Review 5.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

6.  F-18 labeled vasoactive intestinal peptide analogue in the PET imaging of colon carcinoma in nude mice.

Authors:  Dengfeng Cheng; Yuxia Liu; Hua Shen; Lifang Pang; Duanzhi Yin; Yongxian Wang; Shanqun Li; Hongcheng Shi
Journal:  Biomed Res Int       Date:  2013-12-26       Impact factor: 3.411

Review 7.  Review: Receptor Targeted Nuclear Imaging of Breast Cancer.

Authors:  Simone U Dalm; John Fred Verzijlbergen; Marion De Jong
Journal:  Int J Mol Sci       Date:  2017-01-26       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.